PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för luminespib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

18 hits

Bibliografisk träff 2014-11-05

Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.

Taniguchi H, Hasegawa H, Sasaki D, Ando K, Sawayama Y, Imanishi D, Taguchi J, Imaizumi Y, Hata T, Tsukasaki K, Uno N, Morinaga Y, Yanagihara K, Miyazaki Y.

Cancer Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cas.12540

Bibliografisk träff 2014-08-01

89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.

Gaykema SB, Schröder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, Bongaerts AH, Akimov M, Fernandez-Ibarra C, Lub-de Hooge MN, de Vries EG, Swanton C, Banerji U.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-14-0491

Bibliografisk träff 2014-07-29

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.

Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R.

PLoS One · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0103680

Bibliografisk träff 2014-07-12

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.

Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SB, Lub-de Hooge MN, Kosterink JG, de Vries EG, Schröder CP.

Eur J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejca.2014.06.008

Bibliografisk träff 2014-05-01

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.

Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.1706

Bibliografisk träff 2014-02-13

A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes.

Gillan V, O'Neill K, Maitland K, Sverdrup FM, Devaney E.

PLoS Negl Trop Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pntd.0002699

Bibliografisk träff 2013-10-01

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ.

Toxicol Appl Pharmacol · journal article · DOI 10.1016/j.taap.2013.09.018

Bibliografisk träff 2013-03-14

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.

Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-12-0998

Bibliografisk träff 2013-03-01

Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.

Okui T, Shimo T, Fukazawa T, Mohammad Monsur Hassan N, Honami T, Ibaragi S, Takaoka M, Naomoto Y, Sasaki A.

Curr Cancer Drug Targets · comparative study; research support, non-u.s. gov't; journal article · DOI 10.2174/1568009611313030007

Bibliografisk träff 2013-01-29

The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.

Walsby EJ, Lazenby M, Pepper CJ, Knapper S, Burnett AK.

Br J Haematol · journal article · DOI 10.1111/bjh.12215

Bibliografisk träff 2013-01-20

Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines.

Hartmann S, Günther N, Biehl M, Katzer A, Kuger S, Worschech E, Sukhorukov VL, Krohne G, Zimmermann H, Flentje M, Djuzenova CS.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2012.12.027

Bibliografisk träff 2012-11-29

Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.

Hsueh YS, Yen CC, Shih NY, Chiang NJ, Li CF, Chen LT.

Autophagy · research support, non-u.s. gov't; research-article; journal article · DOI 10.4161/auto.22802

Bibliografisk träff 2012-10-09

Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.

Bao XH, Takaoka M, Hao HF, Fukazawa T, Yamatsuji T, Sakurama K, Takigawa N, Nakajima M, Fujiwara T, Naomoto Y.

Oncol Rep · journal article · DOI 10.3892/or.2012.2074

Bibliografisk träff 2012-07-18

Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.

Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, Chang PM, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CY.

Cancer · research support, non-u.s. gov't; journal article · DOI 10.1002/cncr.27743

Bibliografisk träff 2012-07-01

Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.

Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, Geissler EK, Stoeltzing O.

Anticancer Res · research support, non-u.s. gov't; journal article

Bibliografisk träff 2012-05-01

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.

Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.491

Bibliografisk träff 2012-04-16

The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.

Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, Huddart RA, Harrington KJ.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0035436

Bibliografisk träff 2012-04-01

Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.

Djuzenova CS, Blassl C, Roloff K, Kuger S, Katzer A, Niewidok N, Günther N, Polat B, Sukhorukov VL, Flentje M.

Cancer Biol Ther · research support, non-u.s. gov't; journal article · DOI 10.4161/cbt.19294